Valiant Laboratories DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.65×−4.25×1.46×−0.42×
0.99×2.19×0.22×0.07×
8.1%0.1%−5.1%−5.7%
0.55×0.55×0.36×0.53×
1.49×1.49×1.71×1.45×
4.3%−1.1%−1.0%0.1%
−1.2%−1.2%−0.9%0.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VALIANTLAB₹128.33

Valiant Laboratories Limited

· Pharma & Health
₹ CrorePeersALBERTDAVDHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURYMcap ₹697 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×-0.421.46-4.250.65
Interest Burden (Pretax/EBIT) ×0.070.222.190.99
EBIT Margin %-5.70-5.080.158.14
Asset Turnover ×0.530.360.550.55
Financial Leverage (Assets/Equity) ×1.451.711.491.49
ROE (5-step product, year-end total equity) %0.13-1.02-1.134.29
ROE (owners' profit / average owners' equity) %0.13-0.93-1.20-1.20
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.